The production of polyamines has been shown to be an effective target for a drug against the West African form of sleeping sickness caused by Trypanosoma brucei gambiense. T. brucei belongs to the group of protozoan parasites classed as trypanosomatids. Parasitic species of this group are the causative agents of various tropical diseases besides African sleeping sickness, e.g. Chagas' disease (Trypanosoma cruzi), cutaneous (Lesihmania spp.) and visceral (Leishmania donovani) leishmaniasis. The metabolism of polyamines in the parasites is a potential target for the development of new drugs for treatment of these diseases. The key steps in polyamine synthesis are catalysed by ODC (ornithine decarboxylase) and AdoMetDC (S-adenosylmethionine decarboxylase). In the present paper, some of the available information on ODC and AdoMetDC in trypanosomatids will be described and discussed.
Introduction
Infectious diseases caused by protozoan parasites represent a major public health problem around the world. It is estimated that almost 50% of the world's population is at risk and approx. 500 million people suffer from illnesses related to these diseases each year (http://www.who.int/tdr/index.html). The drugs available against these diseases are still of relatively low potency and/or high toxicity, and, despite much effort, very few highly effective drugs have been developed in recent years. Hence there is an urgent need for the development of new drugs in this area.
The polyamine biosynthetic pathway has been demonstrated to be a successful target for treatment of the West African form of sleeping sickness, caused by the protozoan parasite Trypanosoma brucei gambiense [1, 2] . The drug used is eflornithine, also known as DFMO (difluoromethylornithine), which is a highly specific irreversible inhibitor of the enzyme catalysing the first step in polyamine biosynthesis, namely ODC (ornithine decarboxylase). The drug was initially developed as a cancer drug targeting mammalian ODC, but was later also demonstrated to be effective against parasites causing human sleeping sickness [3] . In addition, drugs targeting AdoMetDC (adenosylmethionine decarboxylase), which catalyses another key enzyme in the polyamine biosynthetic pathway, have been shown to be effective against these parasites [4, 5] . T. brucei belongs to the group of closely related protozoan parasites classed as trypanosomatids. Parasitic species of this group are the causative organisms of various tropical diseases besides African sleeping sickness, e.g. Chagas' disease (Trypanosoma cruzi), and cutaneous (Lesihmania spp.) and visceral (Leishmania donovani) leishmaniasis. The trypanosomatids contain a unique redox system, in which trypanothione replaces the general glutathione system [6, 7] . Trypanothione [bis(glutathionyl)spermidine] is synthesized from spermidine, which is the major polyamine in these parasites [6, 7] . Thus interference with their polyamine production may make them more vulnerable to the oxidative defence encountered in the human host. However, DFMO is not very effective against trypanosomatids other than T. brucei, indicating important differences. Some of these differences may be in the target of the drug, namely ODC. The key enzymes in the polyamine biosynthetic pathway, ODC and AdoMetDC, have been cloned and characterized from a variety of trypanosomatids, including those causing tropical diseases [8] [9] [10] [11] [12] [13] [14] . Some of the available information is presented and discussed in the present paper.
ODC
ODC catalyses the first step in the polyamine biosynthetic pathway, which is conversion of ornithine into putrescine. In mammalian cells, ODC is highly regulated and its turnover is extremely rapid with half-lives of usually less than 1 h [3, 15] . In contrast with the mammalian enzyme, ODC has been demonstrated to be a stable enzyme in the trypanosomatids T. brucei [8, 16] and L. donovani [9] . The slow turnover of T. brucei ODC is suggested to contribute to the effectiveness of the ODC inhibitor DFMO against the West African form of sleeping sickness [8] . DFMO is an enzyme-activated irreversible inhibitor of ODC. If the enzyme has a slow turnover, the enzyme will be inactive for a long time. However, if ODC has a fast turnover, the inactivated enzyme molecule will be rapidly replaced by newly synthesized enzymatically active ODC molecules.
Like other short-lived proteins mammalian ODC is degraded by the 26 S proteasome [15, 17] . However, ODC degradation is not triggered by ubiquitination which otherwise is the usual mechanism for targeting proteins for degradation by the 26 S proteasome [18] . Instead, the degradation of ODC by the 26 S proteasome appears to be induced by the binding of an inducible protein named antizyme to the enzyme [15, 19] . The polyamines induce the degradation of ODC by affecting the synthesis of antizyme. The synthesis of antizyme is dependent on a unique mechanism involving ribosomal frame shifting [20] . Besides targeting ODC for degradation, the binding of antizyme inactivates the enzyme. Antizyme binds to the monomer of ODC with a very high affinity, which results in a shift from enzymatically active dimers to enzymatically inactive monomers.
Molecular analysis of mammalian ODC has revealed that the C-terminal part of the enzyme is crucial for the rapid degradation of the enzyme [21, 22] . Truncations or mutations in this part of the ODC protein convert the enzyme into a metabolically stable protein. It is believed that the binding of antizyme to ODC induces some kind of structural changes exposing the C-terminal end of the protein to the 26 S proteasome [23] . ODCs from T. brucei and L. donovani, both of which are stable proteins, lack this C-terminal domain [8, 9] . Furthermore, combining T. brucei ODC with the C-terminus of mammalian ODC confers a short halflife to the fusion protein when expressed in mammalian cells [16, 24] . Interestingly, the C-terminal part of mammalian ODC contains a so-called PEST region, which are regions rich in proline (P), glutamic acid (E), aspartic acid (D), serine (S) and threonine (T). These regions have been shown to be more abundant in proteins with short half-lives, indicating a role in the rapid turnover of the protein [25] .
Both T. brucei and L. donovani are digenetic parasites which inhabit two highly specific hosts during their life cycle. Dr Israel Algranati and colleagues discovered that some monogenetic trypanosomatids, such as Crithida fasciculata and Phytomonas T274, contain ODCs with short half-lives [26, 27] . C. fasciculata is a monogenetic trypanosomatid that grows in the digestive tract of infected flies and Phytomonas T274 is a plant trypanosomatid. Algranati and colleagues demonstrated that inhibiting protein synthesis in C. fasciculata and Phytomonas T274 with cycloheximide resulted in a rapid decrease in ODC activity with a half-life of approx. 30 min [26, 27] .
The cloning of the gene encoding C. fasciculata ODC revealed a high degree of sequence homology with ODC from L. donovani [10] , with an identity of approx. 70% between the two sequences. Both ODCs from C. fasciculata and L. donovani contain long N-terminal extensions of more than 200 amino acids compared with ODCs from T. brucei and mouse [10] . The sequencing of C. fasciculata ODC also revealed that this protein lacks the region corresponding to the C-terminal domain of mammalian ODC, indicating that C. fasciculata ODC contains other signals targeting the enzyme for rapid degradation [10] . Although C. fasciculata ODC does not have a region corresponding to the C-terminal part of mammalian ODC (which contains a PEST sequence), it has two regions which contain sequences which fulfil the requirements of a PEST region. One is located in the N-terminal extension and the other is located close to the C-terminal end [10] . The PEST sequence in the N-terminal extension is a very strong PEST sequence according to the algorithm by Rogers et al. [25] . Both these PEST regions are missing in the mammalian ODC. Although there is a strong homology between C. fasciculata ODC and L. donovani ODC, the latter does not have a region corresponding to the first PEST region of C. fasciculata ODC. Nevertheless, L. donovani ODC has a PEST sequence close to the C-terminal end, corresponding to the second PEST region of C. fasciculata ODC, although this is a much stronger PEST sequence in C. fasciculata ODC than in L. donovani ODC. Thus L. donovani ODC, which is a metabolically stable enzyme, lacks the N-terminal PEST region and has a much weaker second PEST region compared with C. fasciculata ODC, which is a metabolically unstable enzyme [9, 10] . However, it should be stressed that the importance of these PEST regions for the rapid turnover of C. fasciculata ODC remains to be confirmed.
Interestingly, C. fasciculata ODC is also rapidly degraded in mammalian cells as well as in a rabbit reticulocyte lysate system, whereas L. donovani ODC is not [10, 28] . The rabbit reticulocyte lysate contains all the components necessary for degradation of mammalian ODC by the 26 S proteasome, and changes in the ODC protein sequence which affect the half-life in vivo also affect the degradation rate in the reticulocyte lysate [22] . Thus C. fasciculata ODC contains degradation signals that are also functionally active in mammalian cells. Inhibitors of the 26 S proteasome markedly reduce the degradation rate of C. fasciculata ODC in the mammalian systems, indicating the involvement of the 26 S proteasome in the degradation of C. fasciculata ODC in mammalian cells [28] . However, whether C. fasciculata ODC is degraded by a similar proteolytic system in the parasite is not known. Nevertheless, in contrast with the degradation of mammalian ODC, the degradation of C. fasciculata ODC does not seem to be induced by a protein corresponding to the mammalian antizyme [28] .
As mentioned above, DFMO is highly effective against the parasite T. brucei gambiense causing the West African form of sleeping sickness. This has, at least partly, been suggested to be due to fact that ODC in T. brucei is a stable enzyme [8] and that polyamines are substrates for the synthesis of trypanothione [6, 7] , which is essential for the protection of the parasite against reactive oxygen species produced by the host. However, DFMO is not very effective against the trypanosomatid parasite causing visceral leishmaniasis, L. donovani, in spite of the fact that this parasite also has a stable ODC and uses polyamines for trypanothione production. DFMO was originally developed as a cancer agent for use against mammalian ODC. It is conceivable that it may be less effective as an inhibitor of ODCs from these protozoan parasites, which are highly separated phylogenetically from mammals. However, a recent report suggests that the Odc gene in T. brucei has been replaced by an Odc gene from a vertebrate source [29] . Eukaryotic phylogenies from fulllength genes for ODC revealed that the Odc genes from various African trypanosomes (T. brucei, Trypansoma congolense and Trypanosoma vivax) clustered with Odc genes from vertebrates rather than with Odc genes from other trypanosomatids, indicating a horizontal gene transfer from a vertebrate species [29] . The conclusion of a loss of the Odc gene in the Trypanosoma lineage followed by acquisition of a new copy from a vertebrate host in the African branch of the genus was supported by analysis of the regions around the Odc genes in Leishmania major, T. brucei and T. cruzi [29] .
DFMO has been demonstrated to be without effect on Chagas' disease, which is the American form of trypanosomiasis. The causative agent of Chagas' disease is T. cruzi, which is closely related to T. brucei. All attempts to measure any ODC activity in this parasite have been unsuccessful and it was suggested that the parasite contains an alternative pathway for the production of putrescine from arginine, via agmatine [30] . However, gene analysis as well as metabolic studies using radiolabelled ornithine and arginine together with the relevant enzyme assays indicate that T. cruzi is unable to synthesize significant amounts of putrescine, and is dependent on scavenging this diamine from an external source (like the host) [31] [32] [33] . The parasite has been shown to contain highly effective high-affinity transporters for the uptake of putrescine [34] and spermidine [35] . Thus, during evolution, T. cruzi may have developed into a putrescine auxotrophic parasite by the loss of its Odc gene. T. cruzi replicates inside a cell in the host and it is conceivable that it may scavenge putrescine or other polyamines from the host cell. T. brucei, on the other hand, replicates extracellularly in the bloodstream of the host and is thus more dependent on endogenous polyamines (the polyamine concentration in blood is relatively low). The introduction of the Odc gene from C. fasciculata into the genome of T. cruzi makes the parasite overcome the exogenous putrescine requirement for growth [36] . Interestingly, the C. fasciculata is a stable enzyme when expressed in T. cruzi [36] . The recent identification and characterization of a polyamine transporter from L. major may facilitate the identification of the specific putrescine transporter responsible for the uptake of putrescine in T. cruzi [37] . The molecular characterization of this transporter may form the basis for future design of specific drugs against Chagas' disease.
AdoMetDC
AdoMetDC catalyses the production of decarboxylated AdoMet, which provides the aminopropyl groups in the synthesis of spermidine and spermine from putrescine and spermidine respectively. Also, mammalian AdoMetDC is a highly regulated enzyme with a fast turnover [38] . Like ODC, mammalian AdoMetDC appears to be degraded by the 26 S proteasome [39] . However, so far not much is known about the mechanisms involved. Unlike the degradation of ODC, the degradation of AdoMetDC is not affected by polyamines. Furthermore, no AdoMetDC-binding protein similar to antizyme has yet been discovered. Instead, it is conceivable that the degradation of mammalian AdoMetDC by the 26 S proteasome is ubiquitin-dependent [39] . Nevertheless, the synthesis of AdoMetDC is highly regulated by the cellular polyamine levels [38] . Spermidine and spermine inhibit the synthesis of AdoMetDC at the levels of transcription as well as translation. Mammalian AdoMetDC is synthesized as a pro-enzyme, which has to be cleaved in order to produce the two different subunits of the enzyme (which is a heterotetramer containing two subunits of each) [40] . The cleavage of the proenzyme generates a pyruvate covalently bound to the larger subunit [40] . Mammalian AdoMetDC is one of the very few enzymes that use pyruvate, instead of pyridoxal 5 -phosphate, as a cofactor [41] . The conversion of the AdoMetDC proenzyme into the subunits is stimulated in vitro by putrescine [42] . Putrescine also exerts a direct stimulatory effect on the activity of the enzyme [42] .
AdoMetDC in trypanosomatids has been demonstrated to be a potential target for drugs against various diseases caused by protozoan parasites of this group [4, 5] . However, the molecular understanding of AdoMetDC and its regulation in trypanosomatids is much more meagre than that of the mammalian enzyme. AdoMetDC appears to be a stable enzyme in T. brucei [43] as well as in L. donovani [13] . No reports exist describing the half-life of T. cruzi AdoMetDC. Analysis of AdoMetDC in C. fasciculata showed that the enzyme has a very fast turnover in the parasite, with a halflife as short as 3 min, which appears to be the shortest half-life ever recorded for a eukaryotic AdoMetDC [44] . As for the mammalian enzyme, putrescine has a direct stimulatory effect on AdoMetDCs from T. brucei [45] , T. cruzi [11, 46] and C. fasciculata [44] . No information on whether this is true also for AdoMetDC from Leishmania spp. is available, but it is highly likely.
AdoMetDC have been cloned and sequenced from a variety of trypanosomatids, e.g. T. brucei (GenBank R accession number U20092), T. cruzi [11] , L. donovani [13] , Leishmania infantum [14] and C. fasciculata (L. Persson, unpublished work). The enzymes exhibited high homology between the various trypanosomatid species (with identity values ranging between 62 and 85%), but less with the mammalian enzyme (30-33% identity). Interestingly, there is a close homology (85% identity) between C. fasciculata AdoMetDC and L. donovani AdoMetDC, in spite of the large difference in turnover rates in the parasites (L. Persson, unpublished work). The trypanosomatid AdoMetDCs are very similar in size, with molecular masses of approx. 42-44 kDa, which is somewhat bigger than that of mammalian AdoMetDC (38 kDa). All of the trypanosomatid AdoMetDCs contain a highly conserved region around an ESS (Glu-Ser-Ser) sequence. This is similar to the site in mammalian AdoMetDC where the cleavage of the proenzyme into the two subunits occurs. The cleavage occurs between the glutamic acid and the serine residues, which also transforms the serine into the covalently bound pyruvate. In contrast with the processing of mammalian AdoMetDC, putrescine does not appear to stimulate the conversion of the trypanosomatid AdoMetDC pro-enzyme into the two subunits as studied in a rabbit reticulocyte lysate using AdoMetDC from T. cruzi [46] and C. fasciculata (L. Persson, unpublished work).
Conclusions
The polyamine biosynthetic pathway in various trypanosomatids is a potential target for drugs against various diseases caused by these protozoan parasites. The target has been validated using different enzyme inhibitors [1, 47] , as well as null mutants of some of the parasites, i.e. T. brucei [48] and L. donovani [13, 49, 50] . The understanding of species-specific differences in the enzymes involved in parasitic polyamine production may form the basis for future design of drugs targeting these parasites.
